Versatile Biotech Developing Optimal Biotherapeutics
Kaigene is dedicated to developing innovative therapeutic antibodies and fusion proteins to address the significant clinical unmet needs of rare autoimmune diseases. Our mission is to improve the lives of patients by harnessing the power of cutting-edge science and delivering breakthrough treatments.
Autoimmune disease is a complex medical condition in which the immune system mistakenly identifies normal self-tissues as foreign and attacks them. Our goal is to identify novel immune targets and develop safe and effective treatments that can address the underlying mechanisms driving autoimmune disease, ultimately improving the lives of patients living with these conditions.
We have meticulously crafted a diverse pipeline of six optimal biotherapeutics, encompassing both best-in-class and first-in-class antibodies and fusion proteins. Each of these innovative assets targets a unique immune mechanism, highlighting our commitment to addressing the unmet needs of patients suffering from autoimmune diseases.
We are actively seeking exceptional talent with a strong passion for new biotherapeutics development. we invite you to join our team and contribute to a brighter future. As part of our team, you'll gain invaluable experience across the entire spectrum of drug development.
Kaigene, a leading biotech company focused on developing innovative therapeutic antibodies for rare autoimmune diseases, has announced its participation in the upcoming BIO 2023 convention.This event, held annually by the Biotechnology Innovation Organization, is recognized globally as the largest gathering of biotechnology companies, academic institutions, state biotechnology centers, and related organizations.Kaigene will showcase its diverse portfolio of six optimal biotherapeutics, each targeting a unique immune target. The portfolio includes two best-in-class and four first-in-class antibodies and fusion proteins."We are thrilled to be part of this event," said Minjae Shin, CEO of Kaigene. "It provides an excellent platform for us to share our progress and vision with industry peers and potential partners. We look forward to engaging in meaningful conversations about the future of therapeutic antibody development."The BIO 2023 Convention will serve as a unique opportunity for Kaigene to connect with thought leaders, potential collaborators, and industry influencers in the biotech sector.Keep an eye out for more information on Kaigene's participation in the BIO 2023 Convention in the coming weeks.
North Bethesda, September 1st, 2022Kaigene, a leading biotechnology company focused on the development of innovative antibodies and fusion proteins for the treatment of autoimmune diseases, is excited to announce the grand opening of its cutting-edge Research and Development (R&D) center in North Bethesda, MD, the USA.The newly-established facility marks a significant milestone for Kaigene, as it sets the stage for groundbreaking research and the advancement of its diverse pipeline of six optimal biotherapeutics. The R&D center is equipped with state-of-the-art technology, enabling the company's team of dedicated scientists and researchers to accelerate the development of both best-in-class and first-in-class antibodies and fusion proteins.Strategically located in North Bethesda, Kaigene's R&D center is at the heart of a thriving biotech hub, surrounded by renowned organizations such as the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), as well as numerous biotechnology companies. This prime location facilitates partnerships and collaborations with these institutions while providing access to a pool of top-tier talent.Minjae Shin, CEO of Kaigene, commented on the opening, saying, "Our R&D center represents a bold new chapter in Kaigene's story, as we continue to pursue our mission of revolutionizing patient care through the development of groundbreaking therapeutics. We are eager to harness the full potential of our optimal portfolio strategy, maximizing the probability of success as we strive to address the unmet needs of patients suffering from autoimmune diseases."With the opening of its R&D center in North Bethesda, Kaigene is poised to remain at the forefront of scientific advancements, continuing to drive innovation and deliver life-changing solutions for patients in need.